BRIEF-Acceleron gets FDA orphan designations for blood disorder drug

March 26 (Reuters) - Celgene Corp :

* Acceleron receives two FDA orphan designations for ace-536

* Acceleron pharma-ace-536 granted rare disease designation for treatment of

beta-thalassemia, for treatment of myelodysplastic syndromes

* Acceleron-ace-536 is investigational protein therapeutic,being developed by

acceleron as part of global collaboration with Celgene

* Source text for Eikon * Further company coverage ((Bangalore Newsroom; +1 646 223 8780))

View the original article here